Box 12.7Priorities for Research

While achievements made in the past 15 years give reason for optimism, some gaps and priorities for research remain (Tanner and others 2015):

  • Detection of emergence and spread of drug-resistant parasites using geospatial and temporal mapping of drug resistance
  • Epidemiologically and economically effective and efficient mixes of interventions in different contexts
  • Serological tests to detect individual-level recent infections
  • Sensitive clinical field diagnostic tests
  • New tools for eliminating P. vivax, including the identification of asymptomatic hypnozoite carriers
  • Effective approaches for mass drug administration in different contexts
  • Improved vector control strategies that target residual transmission
  • Continued research and development for a combination vaccine
  • Appropriate models for private sector and community-based surveillance and response
  • Capacity building in program and health system management
  • Estimates of costs to identify and secure laboratory specimens of malaria parasites and to stockpile diagnostic, treatment, and vaccine production capabilities in the future
  • Advocacy for engagement in the eradication agenda
  • Sustained investments in malaria elimination and eradication, including innovative financing mechanisms.

From: Chapter 12, Malaria Elimination and Eradication

Cover of Major Infectious Diseases
Major Infectious Diseases. 3rd edition.
Holmes KK, Bertozzi S, Bloom BR, et al., editors.
© 2017 International Bank for Reconstruction and Development / The World Bank.

This work is available under the Creative Commons Attribution 3.0 IGO license (CC BY 3.0 IGO) http://creativecommons.org/licenses/by/3.0/igo. Under the Creative Commons Attribution license, you are free to copy, distribute, transmit, and adapt this work, including for commercial purposes, under the following conditions:

Attribution—Please cite the work as follows: Patel, V., D. Chisholm., T. Dua, R. Laxminarayan, and M. E. Medina-Mora, editors. 2015. Mental, Neurological, and Substance Use Disorders. Disease Control Priorities, third edition, volume 4. Washington, DC: World Bank. doi:10.1596/978-1-4648-0426-7. License: Creative Commons Attribution CC BY 3.0 IGO

Translations—If you create a translation of this work, please add the following disclaimer along with the attribution: This translation was not created by The World Bank and should not be considered an official World Bank translation. The World Bank shall not be liable for any content or error in this translation.

Third-party content—The World Bank does not necessarily own each component of the content contained within the work. The World Bank therefore does not warrant that the use of any third-party-owned individual component or part contained in the work will not infringe on the rights of those third parties. The risk of claims resulting from such infringement rests solely with you. If you wish to re-use a component of the work, it is your responsibility to determine whether permission is needed for that re-use and to obtain permission from the copyright owner. Examples of components can include, but are not limited to, tables, figures, or images.

All queries on rights and licenses should be addressed to the Publishing and Knowledge Division, The World Bank, 1818 H Street NW, Washington, DC 20433, USA; fax: 202-522-2625; e-mail: gro.knabdlrow@sthgirbup.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.